回生口服液治疗原发性肝癌疗效观察

Clinical Observation on the Effect of Huisheng Oral Liquid for Primary Hepatocellular Carcinoma

目的观察回生口服液联合艾迪注射液及TACE(经导管肝动脉化疗栓塞术)治疗原发性肝癌的疗效。方法 40例原发性肝癌患者,随机分成2组,观察组20例,行回生口服液联合艾迪注射液及TACE治疗原发性肝癌。对照组20例,行艾迪注射液联合TACE治疗原发性肝癌。结果回生口服液具有对肿瘤增长具有抑制作用,能显著改善原发性肝癌患者的临床症状及化验指标,提高病人的生存质量。结论回生口服液对原发性肝癌的治疗有很好的辅助作用。

Objective To observe the curative effect of Huisheng Oral Liquid and Aidi Injection and TACE （transcatheter hepatic arterial chemotherapy embolization） treatment of primary liver cancer. Methods 40 cases of primary liver cancer patients were randomly divided into two groups, the observation group （n= 20）, to supply Huisheng Oral Liquid, Aidi injection and TACE in the treatment of primary liver cancer. The control group （20 cases）, only to supply Aidi injection combined with TACE for primary liver cancer. Results Huisheng Oral Liquid with inhibition of tumor growth, can significantly improve the clinical symptoms and laboratory markers of primary liver cancer patients, improve patient quality of life. Conclusion Huisheng Oral Liquid for the treatment of primary liver cancer have a good supporting role.